Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490]
Publication date
2023-07
Authors
Fassnacht, M.
Assie, G.
Baudin, E.
Eisenhofer, G.
Fouchardiere, C. de la
Haak, H. R.
de Krijger, Ronald R.
Porpiglia, F.
Terzolo, M.
Berruti, A.
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
taverne
Abstract
The authors regret that the legend to Fig. 4 of this publication was given incorrectly. The correction is as follows: For “CVD, cyclophosphamide, vincristine, doxorubicin” read “CVD, cyclophosphamide, vincristine, dacarbazine”. The authors would like to apologise for any inconvenience caused.
Keywords
Taverne, Hematology, Oncology
Citation
Fassnacht, M, Assie, G, Baudin, E, Eisenhofer, G, Fouchardiere, C D L, Haak, H R, de Krijger, R, Porpiglia, F, Terzolo, M, Berruti, A & ESMO Guidelines Committee 2023, 'Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas : ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490]', Annals of Oncology, vol. 34, no. 7, pp. 631. https://doi.org/10.1016/j.annonc.2022.12.006